New hope for rare GIST mutations: regorafenib targets stubborn tumors
NCT ID NCT06087263
First seen Jan 21, 2026 · Last updated Apr 24, 2026 · Updated 18 times
Summary
This study tests whether the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific gene changes (KIT exon 17, 18, or 14, or SDHB deficiency) and have stopped responding to the first treatment, imatinib. About 3 adults with advanced GIST will receive regorafenib, and researchers will monitor side effects and tumor response. The goal is to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.